CCCP (Carbonyl cyanide 3-chlorophenylhydrazone) Clinical Trials

Size	Price	Qty
25mg	USD 147
1g	USD 870

Clinical Trials

A clinical trial sponsored by academic and clinical entities—specifically University Hospital Antwerp and Universiteit Antwerpen—is actively recruiting participants to evaluate patient assessment parameters in obstructive sleep apnea. Listed without a defined interventional phase, the study utilizes baseline clinical findings, including polysomnography measurements, to predict outcomes from drug-induced sleep endoscopy. Overall, this research underscores an ongoing focus on refining diagnostic stratification protocols for patients affected by sleep-disordered breathing conditions.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05267808	Recruiting	Obstructive Sleep Apnea	University Hospital Antwerp\|Universiteit Antwerpen	2022-02-01	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the CCCP (Carbonyl cyanide 3-chlorophenylhydrazone) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

CCCP functions as a protonophore that increases proton permeability across the inner mitochondrial membrane, thereby collapsing the mitochondrial membrane potential and uncoupling oxidative phosphorylation to inhibit downstream STING-mediated interferon-beta production. By inducing acute cellular metabolic stress and mitochondrial dysfunction, this mechanism provides a valuable experimental model for exploring cellular response pathways relevant to hypoxic disorders such as obstructive sleep apnea.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).